Introduction
Hypertension is the preeminent risk factor contributing to the development of cardiovascular disease, including heart failure [1] [2] [3] [4] , and is thereby considered the leading global mortality hazard by the World Health Organization [5] . In hypertension, the elevated cardiac afterload elicits a series of myocardial responses leading to an initial phase of adaptive hypertrophy aimed at maintaining cardiac output to sustain the body's elevated metabolic demand [6] . If the external stress persists, myocardial homeostasis becomes compromised preventing maintenance of the initial adaptive response, at which point hypertrophy turns into chamber enlargement and wall thinning with reduced pumping capacity [6] [7] [8] [9] . This maladaptive remodeling of the ventricle, characterized by activation of inflammatory processes, replacement of cardiomyocytes with fibrotic tissue, reduced capillary density, and overall cellular dysfunction [6] will ultimately progress to heart failure with reduced or preserved left ventricular ejection fraction. As the impact of the hypertension-induced adverse remodeling extends to the atrial chambers, it sets the stage for the development of arrhythmias, in particular atrial fibrillation [10] , increasing thereby the predisposition of the cardiac pump to fail [11] . The main events prompting cardiac hypertrophy in the setting of elevated arterial blood pressure are mechanical stress and neurohumoral stimulation, which have been shown to modulate gene expression, protein synthesis, sarcomere assembly and cell metabolism [12] [13] [14] . When activated chronically and excessively, mechanotransduction and neurohumoral signaling further contribute to the transition from adaptive hypertrophy to maladaptive cardiac remodeling leading to heart failure [7, 15] .
Current therapeutic interventions aimed at reducing the burden of hypertension are guided by initial evidence suggesting a significant effect on mortality imparted by suppression of neurohumoral signaling of the renin-angiotensin system (RAS) with either angiotensin-converting enzyme (ACE) inhibitors or Ang II receptor (AT 1 R) blockers (ARBs) [16] ; randomized clinical trials are published [17] . While the beneficial effects of ACE inhibitors or ARBs in retarding the progression of cardiac dysfunction are documented [18••] , a more critical evaluation of the long-term benefit of high doses of ACE inhibitors and ARBs on cardiovascular mortality in heart failure has found it to be modest [18••] . Likewise, recent meta-analyses reveal a suboptimal efficacy of ACE inhibitors or ARBs in reversing or mitigating the progression of cardiovascular disease [19, 20••, 21•] . Given the vast accumulated evidence demonstrating the contribution of Ang II to adverse cardiovascular remodeling, it is necessary to reconsider whether or not the limited efficacy of current RAS blockers might be partly explained by the inability of these agents to suppress the expression and activity of an independent intracellular RAS.
This review addresses the interplay between the RAS and disease-associated cardiac (mal)adaptive remodeling. We provide a compendium of recent evidence suggesting the need for a shift in the current therapeutic paradigm for hypertension-related cardiovascular disease and highlighting the pivotal contribution of tissuecompartmentalized RAS and intracrine signaling within cardiac myocytes to the progression from an at-risk hypertensive state to overt heart failure. The recently completed Systolic Blood Pressure Intervention trial (SPRINT) underscores the importance of hypertension as a predictor of heart failure since the rate of heart failure occurrence was almost 40% less in patients assigned to the intensive blood pressure treatment [22] .
The Renin-Angiotensin System
Starting with the hallmark discovery of renin by Tigersted and Bergman [23] , extensive knowledge has been accumulated on the nature and characteristics of the RAS over the last 100 years [24, 25•] . Several reviews are available for those less familiar with the biochemical mechanisms involved in the biotransformation of angiotensinogen into biologically active peptides [25•, 26, 27, 28•] . In the context of this presentation, we place emphasis on regulatory mechanisms participating in the generation of Ang II via enzymatic pathways that are not r e n i n -o r A C E -d e p e n d e n t . T h i s n o n -c a n o n i c a l biotransforming pathway for generation of Ang II and the countervailing actions of angiotensin-(1-7) [Ang-(1-7)] are becoming critically important as the overall foundation of the strategies that led to the development of ACE inhibitors, ARBs, and even direct renin inhibitors, were based on the rationale that renin and ACE were the primary enzymes accounting for Ang II generation. As recounted elsewhere, Dr. Ferrario's laboratory was the first to put forward the ideas that led to the characterization of an alternate pathway through which angiotensin I (Ang I) or Ang II could lead to the production of Ang-(1-7) via tissue endopeptidases and the monocarboxy peptidase angiotensin-converting enzyme 2 (ACE2) [28•, 29, 30] . The diversity of biologically active angiotensin peptide functions, and the expression of angiotensin producing genes in tissues other than the kidneys endows the RAS with the capacity to modulate morphogenesis, tissue repair, and regeneration, as well as immunity [31] .
Endocrine Versus Intracrine RAS
Initially described as an exclusively endocrine system regulating blood pressure, the RAS has been recently recognized as a more complex system with extended paracrine and autocrine functions [18••, 25•, 32] . Over the last quarter century, our understanding of the RAS has been further expanded by the characterization of other bioactive derivatives of angiotensinogen, most notably Ang-(1-7) [33] and Ang-(1-9) [34] . More recently, two alternate shorter forms of the angiotensinogen substrate have been identified by Japanese investigators at Miyazaki, Japan. Nagata et al. The aforementioned alternative biosynthetic pathways seem to be the most prominent in tissues rather than in the circulation [18••] . Cytoplasmic levels of Ang-(1-12) in cardiomyocytes are increased in spontaneously hypertensive rats (SHR) compared to Wistar Kyoto (WKY) controls, following an expression pattern similar to Ang I and Ang II but not angiotensinogen [37] . Further studies demonstrated that Ang-(1-12) is indeed an endogenous precursor for intracellular Ang II formation, and that this alternate substrate is regulated independently from the circulating RAS [18••] . Furthermore, Ang-(1-12) metabolism into Ang I or Ang II occurs through a non-renin-dependent pathway as documented in anephric rats [38] , or following the administration of a specific rat renin inhibitor in the isolated perfused heart of WKY and SHR [39] . In humans, the expression of Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Given the lack of chymase activity in the circulation due to the high concentration of circulating endogenous serine protease inhibitors, and the mainly interstitial and intracellular localization of chymase that is upregulated during ACE inhibition [46••, 47], we have proposed that the Ang-(1-12)/chymase axis constitutes a distinct, non-canonical, tissue-delimited system that accounts for the production of Ang II in cardiomyocytes and its intracrine pathological actions (Fig. 1) [18••] . We have extended these findings to demonstrate intracellular chymase in dog cardiomyocytes after ischemia reperfusion injury [48••] and its production by cardiac fibroblasts during heart failure in the rat [49••]. These new findings underscore that mast cells are not the only source of chymase in the heart and that there is a yet to be determined mechanism of chymase uptake and/or synthesis in cardiomyocytes.
In recent studies, we have extended the importance of chymase as an Ang II-forming enzyme through the demonstration that rat chymase catalytic efficiency (ratio of V max / K m ) for Ang-(1-12) is 15-fold higher than for the Ang I substrate [50•]. Several studies in the rat have documented the functionality of Ang-(1-12) as an Ang II-forming substrate [51] [52] [53] [54] [55] [56] [57] [58] including the observation of antihypertensive effect through immunoneutralization of cerebrospinal fluid Ang-(1-12) in transgenic hypertensive rats [59] . Studies in intact rats [35••] , the isolated heart [60] , CHO cells transfected with AT 1 R [54] , or intracellular Ang-(1-12) injection into WKY cardiac myocytes [61••] demonstrate that the majority of the cellular responses produced by Ang-(1-12) are mediated through AT 1 receptors. Cardiac intracellular Ang-(1-12) actions were manifested as a prolongation of the action potential via a decrease of total potassium current due to activation of protein kinase C [61••] . These findings are of considerable importance as reentrant rhythms are caused by a decline in conduction velocity. Furthermore, our previous study using mRen2 rats indicated that chronic estradiol treatment attenuated ovariectomy-associated increases in cardiac Ang II, chymase gene expression, and mast cell number, in the absence of altered cardiac ACE expression or activity, suggesting that the cardioprotective effects of estradiol may be driven by a local reduction of chymase-dependent Ang II formation [62] . Thus, the characterization of this Ang-(1-12)/chymase axis as an independent intracrine pathway accounting for the trophic, contractile, and pro-arrhythmic Ang II actions in the human heart may explain the less than predicted beneficial actions of ACE inhibitors and ARBs in the evolution of cardiac disease.
An intracrine is defined as a protein or peptide with distinct physiological actions that can traffic between cells and signal intracellularly through interaction with classical receptors or independent thereof [63••] . Intracrines, which can be hormones, growth factors, cytokines, DNA-binding proteins, or enzymes, act in a feed-forward loop that upregulates their synthesis in target cells (which can include the same cell where they were originally synthesized), or the activity of target signaling cascades, thus exerting their effects even when the initial intracrine signal is no longer present. Several components of the RAS are intracrines, including Ang II, Ang- (1-7) , angiotensinogen, ACE, and renin, but it has been suggested that Ang II may be the main effector of intracrine RAS [63••] . If this is the case, development of effective intracellular antagonists of Ang II action should prevent the progression of disease.
Indeed, while Ang II internalization and nuclear binding in cardiac myocytes was demonstrated decades ago, currently available data suggests cardiac intracellular production of both Ang II and Ang-(1-7) as the critical mechanisms accounting for the pathological actions of the RAS [32, 64, 65] . Interestingly, Ang II and Ang-(1-7) have been also shown to exert their local biological activity without mediation of plasma membrane-localized receptors but rather directly inside the cell without intermediate secretion [25•, 65] . It has been reported that intracellular effects of Ang II are not blocked by ARBs. Candesartan does not prevent increased Ang II synthesis in cardiomyocytes exposed to high glucose [66] , while chronic administration of losartan, lisinopril, or both had no effect on cardiac Ang II content [67] . Similar conclusions were obtained in the heart of hypertensive rats chronically medicated with olmesartan [68] . On the other hand, a report demonstrating that losartan may be capable of blocking nuclear Ang II receptors following cell-surface receptor-mediated endocytosis and impede Ang II cellular effects [69] , warrants further studies to unveil the intricacies of the tissue RAS.
Current RAS Therapeutics: Are We Doing All We Can?
Captopril [70, 71] was the first ACE inhibitor to become widely available for clinical use in 1981, and the ARB losartan [72] was first introduced into clinical practice in the mid1990s [73] . Since then, suppressing the activity of the RAS with ACE inhibitors or ARBs has been repeatedly shown to improve the treatment of patients with congestive heart failure, post-myocardial infarction, and chronic renal disease [21•] . Indeed, ACE inhibitors and ARBs have become the cornerstone of treatment for heart failure patients over the past 30 years, as they blunt left ventricular hypertrophy, diminish dilatation of the left ventricle after myocardial infarction, and provide a mortality benefit [74] . A significant number of clinical trials enrolling ≥1000 patients have been completed on the use of ACE inhibitors and ARBs for cardiovascular disorders (Fig. 2) . Although the clinical trial data indicate that ACE inhibitors and ARB therapies provide a significant benefit Fig. 1 Ang II as an intracrine hormone. Schematic diagram of tissuedelimited RAS depicting the enzymatic action of a yet to be determined enzyme and chymase to form Ang-(1-12) and Ang II, respectively, in a cardiac cell. This intracrine system is independent from circulating RAS, as shown in the presence of ACE inhibition and AT 1 R blockade, and is capable of cell-contained production of Ang II, which can then interact with intracellular AT 1 R to exert biological actions. AGT angiotensinogen, Ang I angiotensin I, Ang II Ang II, Ang-(1-12) angiotensin-(1-12), AT 1 R Ang II type 1 receptor compared to placebo (as measured by relative risk reduction for myocardial infarction, stroke, congestive heart failure, cardiovascular hospitalization, and cardiovascular-related mortality), Fig. 2 shows that the benefit across all treatment groups is associated with less than a 40% decrease in the primary endpoints [16, [75] [76] [77] [78] . For example, while treatment with ramipril in the Heart Outcomes Prevention Evaluation (HOPE) trial did reduce the number of high-risk patients experiencing cardiovascular-related mortality, myocardial infarction, or stroke, compared with placebo, 14% of the patients in the treatment group nevertheless experienced a cardiovascular-related event, compared with 17.8% of placebo-treated patients (a 3.8% difference between the two groups) [75] . In the SOLVD (Studies of Left Ventricular Dysfunction) trial [76] , which compared enalapril versus placebo in heart failure, 35.2% (452) of the enalapril patients died, compared with 39.7% (510) of placebo patients. Although the treatment added benefit, a considerable number of treated patients did not survive [76] . In the CHARMAlternative (Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity) trial [79] , in which heart failure patients who did not tolerate ACE inhibitors were randomized to placebo or candesartan, hospitalization or cardiovascular-related death was reported in 33% (n = 334) of candesartan patients versus 40% (n = 406) of placebo patients during a median follow-up of 33.7 months. Once again, the treatment offered benefit compared with placebo, but a considerable number of patients did not survive or experienced an unfavorable outcome [77] . Only a 5-18% relative reduction in the risk of cardiovascular death in patients with chronic heart failure and reduced ejection fraction has been achieved by treatment with ACE inhibitors and ARBs compared to placebo [74] , and combination therapy provides no additive effect [17] , suggesting that while ACE inhibitor and ARB therapies are effective, there is ample room for improvement. Furthermore, clinical trials have struggled to identify a favorable effect of these drugs on symptoms or quality of life [80] [81] [82] [83] , and cardiovascular mortality in heart failure patients remains unacceptably high. Additionally, there is low evidence for superior effectiveness of ACE inhibitors and ARBs in patients with hypertension compared to other therapeutics, suggesting that the benefit of RAS blockade appears to be primarily the result of antihypertensive effects rather than the additional benefit that could be gained from blockade of direct Ang II pathological actions in target organs [21•, 84] .
Considering residual cardiovascular risk as the risk of incident cardiovascular events or progression of established cardiovascular damage persisting in patients treated with ACE inhibitors or ARBs, the need for additional, complementary or alternative therapeutics becomes pressing, as patients face residual risks greater than 70% when treated with current standard therapy. The number needed to treat (NNT), defined as the number of patients who needs to be treated in order to prevent one additional negative outcome, or alternatively as the inverse of the absolute risk reduction, further highlights [77] , CHARM-Added Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity [79] , ELITE Evaluation of Losartan in the Elderly Study [102] , ELITE II the Losartan Heart Failure Survival Study (Evaluation of Losartan in the Elderly Study) [103] , EUROPA European trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease [104] , GISSI-3 Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico [105] , HYVET Hypertension in the Very Elderly Trial [106] , HEAAL Heart failure Endpoint evaluation of Ang II Antagonist Losartan [107] , HOPE Heart Outcomes Prevention Evaluation Study [108] , I-PRESERVE Irbesartan in Heart Failure with Preserved Ejection Fraction Study [109] , LIFE Losartan Intervention For Endpoint reduction Study [78] [119] , VAL-HEFT Valsartan Heart Failure Trial [120] , VALIANT Valsartan in Acute Myocardial Infarction trial [121] , VALUE Valsartan Antihypertensive Long-term Use Evaluation study [122] the shortcomings of current RAS blockade therapy in cardiovascular disease. A recent meta-analysis of the effectiveness of RAS inhibitors to prevent all-cause and cardiovascular death, myocardial infarction, and stroke in hypertensive patients [20••] demonstrated not only that the relative risk reduction by ACE inhibitors and ARBs is modest, but also that the NNT is substantial (116 patients to prevent an additional cardiovascular mortality outcome and 80 to prevent a myocardial infarction for ACE inhibitors; 409 patients to prevent an additional cardiovascular mortality outcome and 336 to prevent a myocardial infarction for ARBs).
Noteworthy, it has been shown that, despite adequate inhibition of ACE, the deleterious effects of Ang II may not always be completely eradicated. Plasma Ang II levels return to normal under long-term ACE inhibition despite a significant drop on treatment initiation [85] while addition of valsartan to the direct renin inhibitor aliskiren augments the antihypertensive effect [86] . Thus, despite significant genetic, molecular, physiological, and clinical evidence for a critical participation of the RAS, and in particular Ang II, in the pathogenesis of cardiovascular disease, the long-term effects of RAS blockade using direct renin inhibitors, ACE inhibitors, and ARBs falls short of expectations.
Why ACE inhibitors and ARBs are not more effective than other antihypertensive drugs on hard endpoints in clinical trials remains a subject of debate. We have proposed that the discrepancy may be accounted for by the inability of these agents to reach the site(s) at which Ang II is generated (i.e., cardiac intracellular sites) [33, 87] . Furthermore, the primary role of chymase rather than ACE [88] [89] [90] [91] [92] [93] 46 ] as an Ang IIforming enzyme in human cardiac and vascular tissues is an additional limiting factor in achieving greater therapeutic benefit. While knowledge as to the importance of chymase as an Ang II-forming enzyme in humans spans over a quarter of a century [44] , the importance of this non-ACE-dependent pathway remains grossly underappreciated and blissfully ignored as a topic of relevance in symposia and leading cardiovascular and hypertension journals. A clinical case for studying the chymase/Ang II axis as an additional (potentially additive) target for inhibition of local RAS comes from preclinical studies of chymase inhibition [94••, 95] . In addition, combined chymase and ACE inhibition, compared to ACE inhibition alone, provides an added benefit in terms of left ventricular function, adverse cardiac remodeling, and survival after myocardial infarction in hamsters [46••].
Conclusions
Recognition that Ang II, the main effector of the RAS, is a potent driver of maladaptive cardiac remodeling increasing the susceptibility to heart failure, has fueled decades of basic, translational, and clinical research aimed at blocking Ang II deleterious actions. ACE inhibitors and ARBs have provided relief for a segment of the population with or at risk for heart failure. The impact of these drugs on morbidity and mortality has been widely recognized, yet it is frequently ignored that a vast majority of treated patients remain at risk for disease progression. There is, therefore, a pressing need for research aimed at finding adjuvant or alternative therapies that can fulfill the promise of providing all patients with safe and effective treatment. Targeting the intracellular RAS, in particular the Ang-(1-12)/chymase axis, provides a novel avenue not only for understanding the complex cellular mechanisms mediating the transition from cardiac tissue remodeling to organ failure, but for potentially improving the efficacy of current therapeutic regimens. Promising animal studies demonstrating added benefit of chymase inhibitors when administered in combination with ACE inhibitors [46••] are a solid foundation to build upon for developing clinically relevant solutions based on interrupting intracrine RAS signaling for the treatment of heart failure.
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